Glyscend Therapeutics
MD - BaltimoreBiotechnology
Focus: Glyscend Therapeutics is a pre-revenue biotech company founded in 2024 focused on oral polymer bariatric bypass technology for metabolic disease. The company is early-stage and headquartered in Baltimore, MD.
Profile data last refreshed 23h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Glyscend Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Glyscend Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GLY-200
ObesityClinical Trials (1)
NCT06259981A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
Phase 2Help build intelligence for Glyscend Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.